Patents Represented by Attorney Elliot Korsen

Find this attorney in the Justia Lawyer Directory

  • Kinase inhibitors
    Patent number: 8148361
    Abstract: The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The Formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1 and IGFR-1, thereby making them useful as anti-cancer agents. The formula (I) compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: November 7, 2007
    Date of Patent: April 3, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rajeev S. Bhide, Anne Marinier
  • Tyrosine kinase inhibitors
    Patent number: 7232826
    Abstract: The present invention provides compounds of Formula I or II that are useful as anti-cancer agents and other diseases that can be treated by inhibiting tyrosine kinase enzymes
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: June 19, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Mark D. Wittman
  • Process for the preparation of rebeccamycin and analogs thereof
    Patent number: 7227019
    Abstract: The present invention relates to a method for making an indolopyrrolocarbazole of the general formula [I], where the method includes the step of reacting a bisindolylmaleimide compound with an oxidizing agent in the presence of an oxygen containing gas at a temperature and for a time sufficient to yield the indolopyrrolocarbazole compound of the general formula [I].
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: June 5, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventor: Jianji Wang
  • Tyrosine kinase inhibitors
    Patent number: 7189716
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents.
    Type: Grant
    Filed: January 5, 2004
    Date of Patent: March 13, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Francis Beaulieu, Carl Ouellet, Kurt Zimmermann, Upender Velaparthi, Mark D. Wittman
  • C-6 modified indazolylpyrrolotriazines
    Patent number: 7148220
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: December 12, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Ashvinikumar V. Gavai, Brian E. Fink, Harold Mastalerz, John F. Kadow
  • Pyrrolotriazine compounds as kinase inhibitors
    Patent number: 7141571
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: November 28, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Ashvinikumar V. Gavai, Gregory D. Vite, Ping Chen, Harold Mastalerz, Derek J. Norris, John S. Tokarski, Yufen Zhao, Wen-Ching Han
  • Therapeutic synergy of anti-cancer compounds
    Patent number: 7132554
    Abstract: This invention relates to a synergistic therapeutic combination of anti-cancer compounds which comprises a) a taxane, and b) a substance that binds to the epidermal growth factor receptor (EGFR) and blocks the ability of epidermal growth factor (EGF) to intitiate receptor activities which results in tumor growth inhibition, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: November 7, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventor: William C. Rose
  • Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
    Patent number: 6844318
    Abstract: This invention is directed to antineoplastic agents conjugated to enzyme-cleavable peptides comprising the amino acid recognition sequence of a membrane-bound and/or cell-secreted peptidase, and to the use of such conjugated compounds as chemotherapeutic agents in the targeted treatment of cancers.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: January 18, 2005
    Assignee: Bristol Myers Squibb Pharma Company
    Inventors: Robert A. Copeland, Charles F. Albright, Andrew P. Combs, Randine L. Dowling, Nilsa R. Graciani, Wei Han, C. Anne Higley, Pearl S. Huang, Eddy W. Yue, Susan V. DiMeo
  • C-4 carbonate taxanes
    Patent number: 6750246
    Abstract: The present invention concerns novel taxane derivatives, their use as antitumor agents, and pharmaceutical formulations. The invention claims compounds of formula I and the use of compounds of formula I or pharmaceutical salts thereof as oral drugs for the treatment of human or veterinary disease. in which: R is phenyl, isopropyl, or tert butyl; R1 is —C(O)Rz in which Rz is (CH3)3CO—, (CH3)3CCH2—, CH3(CH2)3O—, cyclobutyl-, cyclohexyloxy, or (2-furyl); R2 is CH3C(O)O—.
    Type: Grant
    Filed: November 14, 2000
    Date of Patent: June 15, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: John F. Kadow, Harold Mastalerz, Qiufen May Xue, Steven Hansel, Mary Edson Zoeckler, William C. Rose, James G. Tarrant
  • Protein elongation factor 2 as a target for antifungal and antiparasitic agents
    Patent number: 6096511
    Abstract: Inhibition of protein elongation factor 2 provides a target for identifying potential antifungal and antiparasitic compounds. EF2 inhibitors are useful as therapeutic agents against fungal and parasitic infections.
    Type: Grant
    Filed: June 2, 1998
    Date of Patent: August 1, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Jennifer Nielsen-Kahn, Michael C. Justice, Dennis M. Schmatz, Ming-Jo Hsu, Theresa W. Ku
  • Process for making phenyl heterocycles useful as COX-2 inhibitors
    Patent number: 6080876
    Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Grant
    Filed: September 17, 1998
    Date of Patent: June 27, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Ilias Dorziotis, Ioannis Houpis, Kan K. Eng
  • Antagonists of gonadotropin releasing hormone
    Patent number: 6077847
    Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: June 20, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Thomas F. Walsh, Mark T. Goulet, Feroze Ujjainwalla
  • Antagonists of gonadotropin releasing hormone
    Patent number: 6077858
    Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: September 21, 1999
    Date of Patent: June 20, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Feroze Ujjainwalla, Thomas F. Walsh, Matthew J. Wyvratt, Jr., Jonathan R. Young, Lin Chu
  • Antagonists of gonadotropin releasing hormone
    Patent number: 6025366
    Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: February 15, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Thomas F. Walsh, Mark T. Goulet, Feroze Ujjainwalla, Jonathan R. Young
  • Cyclohexapeptidyl propanolamine compounds
    Patent number: 5948753
    Abstract: Certain propanolamine compounds are described which have a cyclohexapeptidyl nucleus and which possess antibiotic activity with physical properties suitable for direct use in therapeutic compositions. A process for their preparation is also described.
    Type: Grant
    Filed: May 4, 1993
    Date of Patent: September 7, 1999
    Assignee: Merck & Co., Inc.
    Inventors: James M. Balkovec, Milton L. Hammond, Robert A. Zambias
  • Substituted quinazolinones bearing acidic functional groups as angiotensin II antagonists
    Patent number: 5441959
    Abstract: Novel substituted quinazolinones of the formula (I) are useful as angiotensin II antagonists.
    Type: Grant
    Filed: August 18, 1993
    Date of Patent: August 15, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Prasun K. Chakravarty, Stephen E. de Laszlo, Tomasz W. Glinka, William J. Greenlee, Nathan B. Mantlo, Arthur A. Patchett
  • Lipopeptide derivatives
    Patent number: 5369093
    Abstract: The present invention is directed to water-soluble derivatives of antibiotic lipopeptides having the formula. ##STR1## wherein R is H or OH and R' is a phosphono, sulfo or acyl radical possessing a charged group at neutral pH.The derivatives are esters but having a charged group, have good solubility properties in aqueous medium, rendering them more useful as therapeutic agents.
    Type: Grant
    Filed: March 15, 1991
    Date of Patent: November 29, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Milton L. Hammond, James M. Balkovec, David J. Mathre